Hofstra University

About: Hofstra University is a education organization based out in Hempstead, New York, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 6341 authors who have published 11896 publications receiving 268028 citations.

Using Social Network Sites: The Effects of Playfulness, Critical Mass and Trust in a Hedonic Context

Abstract: The use of Internet social network sites has become an international phenomenon. These websites enable computer-mediated communication between people with common interests such as school, family, and friendship. Popular sites include MySpace and Facebook. Their rapid widespread usage warrants a better understanding. This study contributes to our understanding by empirically investigating factors influencing user adoption of these sites. We introduce the Social Network Site Adoption model to examine the effect of perceptions of normative pressure, playfulness, critical mass, trust, usefulness, and ease of use on usage intention and actual usage of these sites. Structural equation modeling was used to examine the patterns of inter-correlations among the constructs and to empirically test the hypotheses. All the hypothesized determinants have a significant direct effect on intent to use, with perceived playfulness and perceived critical mass the strongest indicators. Intent to use and perceived playfulness h...

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Abstract: BackgroundNo single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of these patients have been ineligible for the pivotal trials of adjuvant trastuzumab. MethodsWe performed an uncontrolled, single-group, multicenter, investigator-initiated study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in greatest dimension. Patients received weekly treatment with paclitaxel and trastuzumab for 12 weeks, followed by 9 months of trastuzumab monotherapy. The primary end point was survival free from invasive disease. ResultsThe median follow-up period was 4.0 years. The 3-year rate of survival free from invasive disease was 98.7% (95% confidence interval [CI], 97.6 to 99.8). Among the 12 relapses seen, 2 were due to distant metastatic breast cancer. Excluding contralateral HER2-negative breast cancers and nonbreast cancers, 7 disease-specific events were noted. A total ...